---
title: "Xtandi (enzalutamide) in castration-resistant prostate cancer: Clinical trials questions"
description: "Clinical trials questions on Xtandi (enzalutamide) in castration-resistant prostate cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Study results. Questions: How much does Xtandi delay metastasis vs placebo in nonmetastatic CRPC (PROSPER)? Xtandi in nonmetastatic CRPC: do patients live longer than with placebo (PROSPER)? Does Xtandi delay new cancer therapy in nonmetastatic CRPC (PROSPER)? Who was enrolled in the Xtandi PROSPER trial for nonmetastatic CRPC? 8 further questions follow. 12 questions quoted from 5 sources."
canonical: "https://www.evicenter.com/medical-information/xtandi--castration-resistant-prostate-cancer/clinical-trials"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Xtandi (enzalutamide) in castration-resistant prostate cancer: Clinical trials questions

Manufacturer: Astellas Pharma US, Inc.; Pfizer Inc.  
Prescribing information: [Xtandi](https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf)

Questions that apply to every indication of Xtandi are on [Xtandi (enzalutamide), all indications](https://www.evicenter.com/medical-information/xtandi).

## Study results

<a id="xtandi-prosper-metastasis-free-survival"></a>

### How much does Xtandi delay metastasis vs placebo in nonmetastatic CRPC (PROSPER)?

Applies to: Non-metastatic castration-resistant prostate cancer (PROSPER)

> “In the PROSPER trial, XTANDI + GnRH therapy* significantly extended metastasis-free survival<sup>†</sup> in patients with nmCRPC<sup>1</sup>
>
> PRIMARY ENDPOINT
> METASTASIS-FREE SURVIVAL
> 71
> %
> reduction in the risk of metastasis or death
> with XTANDI + GnRH therapy* (n = 933) vs placebo + GnRH therapy* (n = 468)
> (HR = 0.29 [95% CI, 0.24-0.35]; P < 0.0001)
> Number of events: 219 (23.5%) with XTANDI + GnRH therapy* vs 228 (48.7%) with placebo + GnRH therapy*<sup>1</sup>”

Source: [XTANDI: XTANDI® (enzalutamide) | Treatment for nmCRPC & mCRPC, captured 2026-11-13](https://www.xtandihcp.com/crpc/home#:~:text=In%20the%20PROSPER%20trial%2C%20XTANDI,%2848.7%25%29%20with%20placebo%20%2B%20GnRH)

> “*Or after bilateral orchiectomy.<sup>1</sup>”

Source: [XTANDI: XTANDI® (enzalutamide) | Treatment for nmCRPC & mCRPC, captured 2026-11-13](https://www.xtandihcp.com/crpc/home#:~:text=%2AOr%20after%20bilateral)

> “<sup>†</sup>The primary endpoint of the study was metastasis-free survival, defined as the time from randomization to whichever of the following occurred first: 1) loco-regional and/or distant radiographic progression per blinded independent central review; or 2) death up to 112 days after treatment discontinuation without evidence of radiographic progression.<sup>1</sup>”

Source: [XTANDI: XTANDI® (enzalutamide) | Treatment for nmCRPC & mCRPC, captured 2026-11-13](https://www.xtandihcp.com/crpc/home#:~:text=primary%20endpoint%20of%20the%20study,discontinuation%20without%20evidence%20of%20radiographic)

> “Metastasis-free survival 
>       Number of Events (%) 
> 219 (23.5) 
> 228 (48.7) 
>       Median, months (95% CI)<sup>1</sup> 
> 36.6 (33.1, NR) 
> 14.7 (14.2, 15.0) 
>       Hazard Ratio (95% CI)<sup>2</sup> 
> 0.29 (0.24, 0.35) 
>       P-value<sup>2</sup> 
> p < 0.0001”

Source: [XTANDI: Prescribing information, page 25, captured 2026-11-13](https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf#page=25)

Note: In the Prescribing Information table rows, the first value is XTANDI (N = 933) and the second is placebo (N = 468).

<a id="xtandi-prosper-overall-survival"></a>

### Xtandi in nonmetastatic CRPC: do patients live longer than with placebo (PROSPER)?

Applies to: Non-metastatic castration-resistant prostate cancer (PROSPER)

> “KEY SECONDARY ENDPOINT
> OVERALL SURVIVAL
> 27
> %
> reduction in the risk of death
> with XTANDI + GnRH therapy* vs placebo + GnRH therapy*
> (HR = 0.73 [95% CI, 0.61-0.88]; P = 0.0011)
> Number of events: 288 (30.9%) with XTANDI + GnRH therapy* vs 178 (38.0%) with placebo + GnRH therapy*<sup>1</sup>”

Source: [XTANDI: XTANDI® (enzalutamide) | Treatment for nmCRPC & mCRPC, captured 2026-11-13](https://www.xtandihcp.com/crpc/home#:~:text=KEY%20SECONDARY%20ENDPOINT,%2838.0%25%29%20with%20placebo%20%2B%20GnRH)

> “Overall survival<sup>3</sup> 
>       Number of Events (%) 
> 288 (30.9) 
> 178 (38.0) 
>       Median, months (95% CI)<sup>1</sup> 
> 67.0 (64.0, NR) 
> 56.3 (54.4, 63.0) 
>       Hazard Ratio (95% CI)<sup>2</sup> 
> 0.73 (0.61, 0.88) 
>       P-value<sup>2</sup> 
> p = 0.0011”

Source: [XTANDI: Prescribing information, page 25, captured 2026-11-13](https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf#page=25)

> “The pre-specified final analysis of OS occurred 27 months after the MFS analysis.”

Source: [XTANDI: Prescribing information, page 25, captured 2026-11-13](https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf#page=25)

Note: In the Prescribing Information table rows, the first value is XTANDI (N = 933) and the second is placebo (N = 468).

<a id="xtandi-prosper-new-therapy"></a>

### Does Xtandi delay new cancer therapy in nonmetastatic CRPC (PROSPER)?

Applies to: Non-metastatic castration-resistant prostate cancer (PROSPER)

> “The primary efficacy outcome was also supported by a statistically significant delay in time to first use of new 
> antineoplastic therapy (TTA) for patients in the XTANDI arm compared to those in the placebo arm. The median TTA 
> was 39.6 months for patients on XTANDI and was 17.7 months for patients on placebo (HR = 0.21; 95% CI: [0.17, 0.26], 
> p < 0.0001).”

Source: [XTANDI: Prescribing information, page 26, captured 2026-11-13](https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf#page=26)

<a id="xtandi-prevail-overall-survival"></a>

### Xtandi in metastatic CRPC before chemotherapy: do patients live longer (PREVAIL)?

Applies to: Chemotherapy-naive metastatic castration-resistant prostate cancer (PREVAIL)

> “In the PREVAIL trial, XTANDI + GnRH therapy* significantly extended overall survival in patients with mCRPC and significantly reduced the risk of radiographic disease progression<sup>†</sup> in patients with mCRPC<sup>1</sup>
>
> OVERALL SURVIVAL
> CO-PRIMARY ENDPOINT, INTENT-TO-TREAT ANALYSIS<sup>1</sup>
> 23
> %
> reduction in the risk of death
> with XTANDI + GnRH therapy* (n = 872) vs placebo + GnRH therapy* (n = 845)
> (HR = 0.77 [95% CI, 0.67-0.88])
> Number of events: 368 (42%) with XTANDI + GnRH therapy* vs 416 (49%) with placebo + GnRH therapy*<sup>1</sup>”

Source: [XTANDI: XTANDI® (enzalutamide) | Treatment for nmCRPC & mCRPC, captured 2026-11-13](https://www.xtandihcp.com/crpc/home#:~:text=In%20the%20PREVAIL%20trial%2C%20XTANDI,%2849%25%29%20with%20placebo%20%2B%20GnRH)

> “Median overall survival was 35.3 months (95% CI, 32.2-NR) for patients receiving XTANDI + GnRH therapy* vs 31.3 months (95% CI, 28.8-34.2) for those receiving placebo + GnRH therapy*<sup>1</sup>”

Source: [XTANDI: XTANDI® (enzalutamide) | Treatment for nmCRPC & mCRPC, captured 2026-11-13](https://www.xtandihcp.com/crpc/home#:~:text=Median%20overall%20survival%20was%2035.3,those%20receiving%20placebo%20%2B%20GnRH)

> “At a prespecified interim analysis for overall survival, there was a 29% reduction in the risk of death in patients who received XTANDI + GnRH therapy* vs placebo + GnRH therapy* (HR = 0.71 [95% CI, 0.60-0.84]; P < 0.0001)<sup>1</sup>”

Source: [XTANDI: XTANDI® (enzalutamide) | Treatment for nmCRPC & mCRPC, captured 2026-11-13](https://www.xtandihcp.com/crpc/home#:~:text=At%20a%20prespecified%20interim%20analysis,0.71%20%5B95%25%20CI%2C%200.60%2D0.84%5D%3B%20P)

> “A statistically significant improvement in overall survival was demonstrated at the pre-specified interim analysis, 
> conducted after 540 deaths, in patients treated with XTANDI compared to those treated with placebo (Table 10).”

Source: [XTANDI: Prescribing information, page 21, captured 2026-11-13](https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf#page=21)

> “Forty 
> percent of XTANDI-treated and 70% of placebo-treated patients received subsequent therapies for metastatic CRPC that 
> may prolong overall survival.”

Source: [XTANDI: Prescribing information, page 21, captured 2026-11-13](https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf#page=21)

> “An updated survival analysis was conducted when 784 deaths were observed. The median 
> follow-up time was 31 months. Results from this analysis were consistent with those from the pre-specified interim 
> analysis (Table 10, Figure 2).”

Source: [XTANDI: Prescribing information, page 21, captured 2026-11-13](https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf#page=21)

> “At the updated analysis, 52% of XTANDI-treated and 81% of placebo-treated patients had 
> received subsequent therapies that may prolong overall survival in metastatic CRPC. XTANDI was used as a subsequent 
> therapy in 2% of XTANDI-treated patients and 29% of placebo-treated patients.”

Source: [XTANDI: Prescribing information, page 21, captured 2026-11-13](https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf#page=21)

> “Table 10. Overall Survival of Patients Treated with Either XTANDI or Placebo in PREVAIL 
>
> XTANDI  
> (N = 872) 
> Placebo  
> (N = 845) 
> Pre-specified Interim Analysis<sup>1</sup> 
>
>
>     Number of Deaths (%)  
> 241 (28) 
> 299 (35) 
>     Median Survival, months (95% CI) 
> 32.4 (30.1, NR)  
> 30.2 (28.0, NR)  
>     P-value<sup>2</sup> 
> p < 0.0001  
>     Hazard Ratio (95% CI)<sup>3</sup> 
> 0.71 (0.60, 0.84)  
> Updated Survival Analysis<sup>4</sup> 
>
>
>     Number of Deaths (%) 
> 368 (42) 
> 416 (49) 
>     Median Survival, months (95% CI) 
> 35.3 (32.2, NR) 
> 31.3 (28.8, 34.2) 
>     Hazard Ratio (95% CI)<sup>3</sup> 
> 0.77 (0.67, 0.88) 
> NR = Not reached. 
> 1. The data cut-off date is 16 Sep 2013. 
> 2. P-value is derived from an unstratified log-rank test. 
> 3. Hazard Ratio is derived from an unstratified proportional hazards model. Hazard Ratio < 1 favors XTANDI. 
> 4. The data cut-off date is 1 Jun 2014. The planned number of deaths for the final overall survival analysis was ≥ 765.”

Source: [XTANDI: Prescribing information, page 21, captured 2026-11-13](https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf#page=21)

Note: The comparison is XTANDI plus GnRH therapy (or after bilateral orchiectomy) vs placebo plus GnRH therapy in chemotherapy-naive patients with metastatic CRPC. In Table 10 of the Prescribing Information, HR 0.71 is from the pre-specified interim analysis, and HR 0.77 with medians of 35.3 and 31.3 months is from the updated survival analysis; in each table row the first value is XTANDI (N = 872) and the second is placebo (N = 845).

<a id="xtandi-prevail-progression"></a>

### How much does Xtandi delay radiographic progression vs placebo before chemotherapy (PREVAIL)?

Applies to: Chemotherapy-naive metastatic castration-resistant prostate cancer (PREVAIL)

> “RADIOGRAPHIC PROGRESSION-FREE SURVIVAL
> CO-PRIMARY ENDPOINT<sup>1</sup>
> 83
> %
> reduction in the risk of radiographic progression or death
> with XTANDI + GnRH therapy* (n=832) vs placebo + GnRH therapy* (n=801)
> (HR = 0.17 [95% CI, 0.14-0.21]; P < 0.0001)
> Number of events: 118 (14%) with XTANDI + GnRH therapy* vs 320 (40%) with placebo + GnRH therapy*<sup>1</sup>”

Source: [XTANDI: XTANDI® (enzalutamide) | Treatment for nmCRPC & mCRPC, captured 2026-11-13](https://www.xtandihcp.com/crpc/home#:~:text=RADIOGRAPHIC%20PROGRESSION%2DFREE%20SURVIVAL,%2840%25%29%20with%20placebo%20%2B%20GnRH)

> “Median radiographic progression-free survival was not reached (95% CI, 13.8-NR) with XTANDI + GnRH therapy* vs 3.7 months (95% CI, 3.6-4.6) with placebo + GnRH therapy*<sup>1</sup>”

Source: [XTANDI: XTANDI® (enzalutamide) | Treatment for nmCRPC & mCRPC, captured 2026-11-13](https://www.xtandihcp.com/crpc/home#:~:text=Median%20radiographic%20progression%2Dfree%20survival%20was,3.6%2D4.6%29%20with%20placebo%20%2B%20GnRH)

> “Radiographic progression was assessed with the use of sequential imaging and was defined by bone scan identification of 2 or more new bone lesions with confirmation (PCWG2) and/or RECIST 1.1 criteria for progression of soft-tissue lesions. The primary analysis of radiographic progression-free survival utilized centrally reviewed radiographic assessment of progression.<sup>1</sup>”

Source: [XTANDI: XTANDI® (enzalutamide) | Treatment for nmCRPC & mCRPC, captured 2026-11-13](https://www.xtandihcp.com/crpc/home#:~:text=Radiographic%20progression%20was%20assessed%20with,centrally%20reviewed%20radiographic%20assessment%20of)

Note: The comparison is XTANDI plus GnRH therapy (or after bilateral orchiectomy) vs placebo plus GnRH therapy in chemotherapy-naive patients with metastatic CRPC.

<a id="xtandi-prevail-chemotherapy-delay"></a>

### Does Xtandi delay the need for chemotherapy in metastatic CRPC (PREVAIL)?

Applies to: Chemotherapy-naive metastatic castration-resistant prostate cancer (PREVAIL)

> “Time to initiation of cytotoxic chemotherapy was prolonged after XTANDI treatment, with a median of 28.0 months for 
> patients on the XTANDI arm versus a median of 10.8 months for patients on the placebo arm [HR = 0.35 (95% CI: 0.30, 
> 0.40), p < 0.0001].”

Source: [XTANDI: Prescribing information, page 23, captured 2026-11-13](https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf#page=23)

<a id="xtandi-prevail-skeletal-events"></a>

### How did time to first skeletal-related event compare for Xtandi vs placebo (PREVAIL)?

Applies to: Chemotherapy-naive metastatic castration-resistant prostate cancer (PREVAIL)

> “The median time to first skeletal-related event was 31.1 months for patients on the XTANDI arm versus 31.3 months for 
> patients on the placebo arm [HR = 0.72 (95% CI: 0.61, 0.84), p < 0.0001]. A skeletal-related event was defined as 
> radiation therapy or surgery to bone for prostate cancer, pathologic bone fracture, spinal cord compression, or change of 
> antineoplastic therapy to treat bone pain.”

Source: [XTANDI: Prescribing information, page 23, captured 2026-11-13](https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf#page=23)

<a id="xtandi-affirm-overall-survival"></a>

### Does Xtandi improve survival after docetaxel in metastatic CRPC (AFFIRM)?

Applies to: Metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy (AFFIRM)

> “XTANDI + GnRH therapy* extended median overall survival post-docetaxel in patients with mCRPC<sup>1</sup>
>
> AFFIRM was a multinational, randomized, double-blind, placebo-controlled phase 3 trial of XTANDI + GnRH therapy* vs placebo + GnRH therapy* in patients who had received prior docetaxel-based chemotherapy.<sup>1,10</sup>
>
> 18.4 months (95% CI, 17.3-NR) median overall survival for patients receiving XTANDI + GnRH therapy* vs 13.6 months (95% CI, 11.3-15.8) for those receiving placebo + GnRH therapy*<sup>1</sup>
> Number of events: 308 (38.5%) with XTANDI + GnRH therapy* vs 212 (53.1%) with placebo + GnRH therapy*<sup>1</sup>
> Treatment was continued until disease progression,<sup>†</sup> initiation of a new systemic antineoplastic treatment, unacceptable toxicity, or study withdrawal. Progression was first assessed at 13 weeks<sup>1,10</sup>”

Source: [XTANDI: XTANDI® (enzalutamide) | Efficacy Results in nmCRPC & mCRPC, captured 2026-11-13](https://www.xtandihcp.com/crpc/efficacy?mtab=metastatic#:~:text=XTANDI%20%2B%20GnRH%20therapy%2A%20extended,was%20first%20assessed%20at%2013)

> “<sup>†</sup>Disease progression was defined as radiographic progression, a skeletal-related event, or clinical progression. Radiographic progression of soft-tissue disease was defined according to RECIST 1.1. Radiographic progression of osseous disease was defined according to bone scans showing 2 or more new lesions. A skeletal-related event was defined as radiation therapy or surgery to bone, pathologic bone fracture, spinal cord compression, or change in antineoplastic therapy to treat bone pain.<sup>10</sup>”

Source: [XTANDI: XTANDI® (enzalutamide) | Efficacy Results in nmCRPC & mCRPC, captured 2026-11-13](https://www.xtandihcp.com/crpc/efficacy?mtab=metastatic#:~:text=progression%20was%20defined%20as%20radiographic,antineoplastic%20therapy%20to%20treat%20bone)

> “A statistically significant improvement in overall survival was demonstrated at the pre-specified interim analysis at the 
> time of 520 deaths in patients on the XTANDI arm compared to patients on the placebo arm (Table 9 and Figure 1).”

Source: [XTANDI: Prescribing information, page 20, captured 2026-11-13](https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf#page=20)

> “Table 9. Overall Survival of Patients Treated with Either XTANDI or Placebo in AFFIRM 
>
> XTANDI 
> (N = 800) 
> Placebo  
> (N = 399) 
> Number of Deaths (%)  
> 308 (38.5) 
> 212 (53.1) 
> Median Survival, months (95% CI) 
> 18.4 (17.3, NR)  
> 13.6 (11.3, 15.8)  
> P-value<sup>1</sup> 
> p < 0.0001  
> Hazard Ratio (95% CI)<sup>2</sup>  
> 0.63 (0.53, 0.75)  
> NR = Not reached. 
> 1. 
> P-value is derived from a log-rank test stratified by baseline ECOG performance status score (0-1 vs. 2) and mean baseline pain score 
> (BPI-SF score < 4 vs. ≥ 4). 
> 2. 
> Hazard Ratio is derived from a stratified proportional hazards model. Hazard Ratio < 1 favors XTANDI.”

Source: [XTANDI: Prescribing information, page 20, captured 2026-11-13](https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf#page=20)

Note: In the Prescribing Information table rows, the first value is XTANDI (N = 800) and the second is placebo (N = 399).

<a id="xtandi-terrain-vs-bicalutamide"></a>

### How did radiographic progression-free survival compare for Xtandi vs bicalutamide in TERRAIN?

Applies to: Chemotherapy-naive metastatic castration-resistant prostate cancer, compared with bicalutamide (TERRAIN)

> “TERRAIN was a multinational, double-blind, randomized, phase 2 trial comparing XTANDI + GnRH therapy* with bicalutamide + GnRH therapy* in mCRPC patients who were asymptomatic or mildly symptomatic and had not received prior chemotherapy.<sup>1,7</sup>”

Source: [XTANDI: XTANDI® (enzalutamide) | Efficacy Results in nmCRPC & mCRPC, captured 2026-11-13](https://www.xtandihcp.com/crpc/efficacy?mtab=metastatic#:~:text=TERRAIN%20was%20a%20multinational%2C%20double%2Dblind%2C,and%20had%20not%20received%20prior)

> “Number of events: 72 (39%) with XTANDI + GnRH therapy* vs 74 (39%) with bicalutamide + GnRH therapy*<sup>1</sup>”

Source: [XTANDI: XTANDI® (enzalutamide) | Efficacy Results in nmCRPC & mCRPC, captured 2026-11-13](https://www.xtandihcp.com/crpc/efficacy?mtab=metastatic#:~:text=Number%20of%20events%3A%2072%20%2839%25%29,%2839%25%29%20with%20bicalutamide%20%2B%20GnRH)

> “Radiographic progression-free survival was defined as the time from randomization to the first objective evidence of radiographic progression as assessed by ICR or death, whichever occurred first.<sup>1</sup>”

Source: [XTANDI: XTANDI® (enzalutamide) | Efficacy Results in nmCRPC & mCRPC, captured 2026-11-13](https://www.xtandihcp.com/crpc/efficacy?mtab=metastatic#:~:text=Radiographic%20progression%2Dfree%20survival%20was%20defined,ICR%20or%20death%2C%20whichever%20occurred)

> “Median radiographic progression-free survival was 19.5 months (95% CI, 11.8-NR) for patients receiving XTANDI + GnRH therapy* vs 13.4 months (95% CI, 8.2-16.4) for patients receiving bicalutamide + GnRH therapy* (HR = 0.60 [95% CI, 0.43-0.83])<sup>1</sup>”

Source: [XTANDI: XTANDI® (enzalutamide) | Efficacy Results in nmCRPC & mCRPC, captured 2026-11-13](https://www.xtandihcp.com/crpc/efficacy?mtab=metastatic#:~:text=Median%20radiographic%20progression%2Dfree%20survival%20was%2019.5,%28HR%20%3D%200.60%20%5B95%25%20CI%2C)

> “Patients could have received prior bicalutamide, but those whose disease had progressed 
> on prior antiandrogen therapy (e.g., bicalutamide) were excluded.”

Source: [XTANDI: Prescribing information, page 23, captured 2026-11-13](https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf#page=23)

> “Forty-six percent of patients had received prior treatment with 
> bicalutamide while no patients received prior treatment with XTANDI.”

Source: [XTANDI: Prescribing information, page 24, captured 2026-11-13](https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf#page=24)

> “<sup>#</sup>Progression-free survival was defined as the time from randomization to the first progression event, which includes radiographic disease progression, skeletal-related event, initiation of new antineoplastic therapy, and death.<sup>13</sup>”

Source: [XTANDI: XTANDI® (enzalutamide), captured 2026-11-13](https://www.xtandihcp.com/about-xtandi/milestones#:~:text=survival%20was%20defined%20as%20the,of%20new%20antineoplastic%20therapy%2C%20and)

Note: This is the radiographic progression-free survival result that the efficacy page and the Prescribing Information report. The milestones page lists progression-free survival (ICR), defined in the last passage, as the TERRAIN primary endpoint.

## Clinical trials

<a id="xtandi-prosper-design"></a>

### Who was enrolled in the Xtandi PROSPER trial for nonmetastatic CRPC?

Applies to: Non-metastatic castration-resistant prostate cancer (PROSPER)

> “PROSPER enrolled 1401 patients with non-metastatic CRPC who were randomized 2:1 to receive either XTANDI orally 
> at a dose of 160 mg once daily (N = 933) or placebo orally once daily (N = 468). All patients in the PROSPER trial 
> received a gonadotropin-releasing hormone (GnRH) analog or had a prior bilateral orchiectomy. Patients were stratified 
> by Prostate Specific Antigen (PSA) Doubling Time (PSADT) and the use of bone-targeting agents. Patients were required 
> to have a PSA doubling time ≤ 10 months, PSA ≥ 2 ng/mL, and confirmation of non-metastatic disease by blinded 
> independent central review (BICR). PSA results were blinded and were not used for treatment discontinuation. Patients 
> randomized to either arm discontinued treatment for radiographic disease progression confirmed by BICR, initiation of 
> new treatment, unacceptable toxicity, or withdrawal.”

Source: [XTANDI: Prescribing information, page 25, captured 2026-11-13](https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf#page=25)

> “<sup>‡</sup>Progression was defined as at least 3 rising PSA values (PSA1 < PSA2 < PSA3) taken at least 1 week apart despite castrate levels of testosterone (≤ 50 ng/dL) on GnRH therapy or after bilateral orchiectomy.<sup>2</sup>”

Source: [XTANDI: XTANDI® (enzalutamide) | Efficacy Results in nmCRPC & mCRPC, captured 2026-11-13](https://www.xtandihcp.com/crpc/efficacy?mtab=nonmetastatic#:~:text=was%20defined%20as%20at%20least,GnRH%20therapy%20or%20after%20bilateral)

<a id="xtandi-prevail-design"></a>

### Who was enrolled in the Xtandi PREVAIL trial for metastatic CRPC?

Applies to: Chemotherapy-naive metastatic castration-resistant prostate cancer (PREVAIL)

> “PREVAIL was a multinational, double-blind, randomized, placebo-controlled phase 3 trial of XTANDI + GnRH therapy* in patients with mCRPC who were asymptomatic or mildly symptomatic.<sup>1,2</sup>”

Source: [XTANDI: XTANDI® (enzalutamide) | Efficacy Results in nmCRPC & mCRPC, captured 2026-11-13](https://www.xtandihcp.com/crpc/efficacy?mtab=metastatic#:~:text=PREVAIL%20was%20a%20multinational%2C%20double%2Dblind%2C,who%20were%20asymptomatic%20or%20mildly)

> “In PREVAIL, 1717 chemotherapy-naïve patients were randomized 1:1 to receive either XTANDI orally at a dose of 
> 160 mg once daily (N = 872) or placebo orally once daily (N = 845). Patients with visceral metastases, patients with a 
> history of mild to moderate heart failure (NYHA class I or II), and patients taking medications associated with lowering 
> the seizure threshold were allowed. Patients with a previous history of seizure or a condition that might predispose to 
> seizure and patients with moderate or severe pain from prostate cancer were excluded.”

Source: [XTANDI: Prescribing information, page 21, captured 2026-11-13](https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf#page=21)

<a id="xtandi-affirm-design"></a>

### Who was enrolled in the Xtandi AFFIRM trial?

Applies to: Metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy (AFFIRM)

> “AFFIRM was a multinational, randomized, double-blind, placebo-controlled phase 3 trial of XTANDI + GnRH therapy* vs placebo + GnRH therapy* in patients who had received prior docetaxel-based chemotherapy.<sup>1,10</sup>”

Source: [XTANDI: XTANDI® (enzalutamide) | Efficacy Results in nmCRPC & mCRPC, captured 2026-11-13](https://www.xtandihcp.com/crpc/efficacy?mtab=metastatic#:~:text=AFFIRM%20was%20a%20multinational%2C%20randomized%2C,who%20had%20received%20prior%20docetaxel%2Dbased)

> “In AFFIRM, a total of 1199 patients who had received prior docetaxel-based chemotherapy were randomized 2:1 to 
> receive either XTANDI orally at a dose of 160 mg once daily (N = 800) or placebo orally once daily (N = 399). Study 
> treatment continued until disease progression (evidence of radiographic progression, a skeletal-related event, or clinical 
> progression), initiation of new systemic antineoplastic treatment, unacceptable toxicity, or withdrawal. Patients with a 
> previous history of seizure, taking medicines known to decrease the seizure threshold, or with other risk factors for seizure 
> were not eligible [see Warnings and Precautions (5.1)].”

Source: [XTANDI: Prescribing information, page 19, captured 2026-11-13](https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf#page=19)

## Related pages
- [Medical information: Xtandi (enzalutamide): Castration-resistant prostate cancer](https://www.evicenter.com/medical-information/xtandi--castration-resistant-prostate-cancer)
- [Indication](https://www.evicenter.com/medical-information/xtandi--castration-resistant-prostate-cancer/indication)
- [Safety](https://www.evicenter.com/medical-information/xtandi--castration-resistant-prostate-cancer/safety)
- [Dosing and administration](https://www.evicenter.com/medical-information/xtandi--castration-resistant-prostate-cancer/dosing-and-administration)
- [Guidelines](https://www.evicenter.com/medical-information/xtandi--castration-resistant-prostate-cancer/guidelines)
